EHA 2018 | CAR T-cells improve response and CR rates in R/R DLBCL
In relapsed/refractory diffuse large B-cell lymphoma (DLBCL), response rates are poor for salvage treatments and autologous stem cell transplants. Here, Christian Gisselbrecht, MD, of the Hôpital Saint Louis, Paris, France speaks about CAR T-cell therapy in DLBCL. He highlights data from the ZUMA-1 trial (NCT02348216), which demonstrated improved response rates, as well as greatly improved complete remission rates, with CAR T-cells in comparison to the standard of care. Prof. Gisselbrecht also discusses the legislative processes and cost-effectiveness analyses involved in approving CAR T-cell therapies worldwide, as well as potential combination of CAR T-cells with novel therapies to improve response. This video was recorded at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden.
